Evolus (EOLS) Receives “Overweight” Rating from Cantor Fitzgerald

Evolus (NASDAQ:EOLS)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a report issued on Tuesday.

A number of other research firms have also recently weighed in on EOLS. HC Wainwright assumed coverage on Evolus in a report on Thursday, February 14th. They issued a “buy” rating and a $37.00 price target for the company. Zacks Investment Research cut Evolus from a “hold” rating to a “sell” rating in a report on Tuesday, February 5th. Mizuho boosted their price target on Evolus from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Stifel Nicolaus assumed coverage on Evolus in a report on Monday, January 28th. They issued a “buy” rating and a $27.00 price target for the company. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Evolus presently has a consensus rating of “Buy” and an average target price of $30.29.

Shares of EOLS stock opened at $26.57 on Tuesday. The firm has a market cap of $650.51 million and a P/E ratio of -16.92. Evolus has a 1 year low of $6.75 and a 1 year high of $39.50.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.09. Analysts predict that Evolus will post -3.25 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EOLS. IFP Advisors Inc raised its holdings in shares of Evolus by 239.6% in the fourth quarter. IFP Advisors Inc now owns 8,490 shares of the company’s stock worth $101,000 after acquiring an additional 5,990 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Evolus by 860.3% in the third quarter. Wells Fargo & Company MN now owns 5,944 shares of the company’s stock worth $110,000 after acquiring an additional 5,325 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Evolus in the fourth quarter worth $129,000. New York State Common Retirement Fund raised its holdings in shares of Evolus by 75.0% in the fourth quarter. New York State Common Retirement Fund now owns 12,600 shares of the company’s stock worth $150,000 after acquiring an additional 5,400 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in shares of Evolus in the fourth quarter worth $163,000. 19.82% of the stock is owned by institutional investors.

Evolus Company Profile

Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

See Also: How does the Federal Reserve determine interest rates?

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.